Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals NASDAQ: ALNY reported third-quarter 2026 global net product revenue of approximately $1.3 billion, up 52% from a year earlier and 10% sequentially, as growth in its transthyretin, or TTR, franchise continued to drive results.

MarketBeat • 7 hours ago

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript

Seeking Alpha • 6 hours ago

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2026, and reviewed recent business highlights. “Our third quarter results reflect the continued growth of our TTR franchise and advancement of key programs with the potential for transformative patient impact,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “As we co.

Business Wire • 12 hours ago

Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • 9 hours ago

Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates

Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $16.26 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.9 per share a year ago.

Zacks Investment Research • 8 hours ago

Lost Money on Alnylam Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Continues Investigating Possible Securities Fraud After 28.31% Share Price Drop

Investigation follows the July 30, 2026 disclosure regarding Alnylam Pharmaceuticals, Inc.; investors who lost money may have claims to recover their losses Investigation follows the July 30, 2026 disclosure regarding Alnylam Pharmaceuticals, Inc.; investors who lost money may have claims to recover their losses

GlobeNewsWire • 2 hours ago

Alnylam (ALNY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Get a deeper insight into the potential performance of Alnylam (ALNY) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Investment Research • Oct 28, 2026

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial

Alnylam Pharmaceuticals NASDAQ: ALNY outlined early clinical data for brezosiran, an investigational RNA interference therapy for Huntington's disease, reporting dose-dependent reductions in cerebrospinal fluid mutant huntingtin after a single intrathecal dose and plans to begin a placebo-controlled pivotal study in 2027, pending regulatory alignment.

MarketBeat • Oct 26, 2026

Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript

Seeking Alpha • Oct 27, 2026

Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case

Alnylam Pharmaceuticals, Inc.'s shares remain under pressure. Meanwhile, on October 23, Alnylam reported promising clinical data for brezosiran, its investigational treatment for Huntington's disease. Moreover, second-quarter Amvuttra sales surged 105.7% year-on-year to approximately $1.1 billion.

Seeking Alpha • Oct 26, 2026